Posted by Michael Wonder on 29 Jul 2020
Ridgeback Biotherapeutics announces priority review of biologics license application for ansuvimab Ebola treatment
29 July 2020 - Ridgeback Biotherapeutics today announced the U.S. FDA has accepted the biologics license application and granted priority review designation for Ridgeback’s investigational Ebola treatment, ansuvimab (mAb114).
The FDA granted breakthrough therapy designation status to ansuvimab as a treatment for Ebola in September 2019.
